A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

• Status: Unknown status
• Trial end date: 1969-12-31

Summary

Primary objective:

To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma.

Secondary objectives:

1. To determine the disease stabilization rate;

2. To assess the progression-free survival and overall survival;

3. To establish the safety profile;

4. To evaluate the changes of circulating factors indicating the angiogenesis activity and their correlation with objective tumor response.

• Phase: Phase 2

Details

• Lead Sponsor: Far Eastern Memorial Hospital
• Treatments: Tegafur; Thalidomide